Overview
Bangladesh’s healthcare and pharmaceutical sectors represent dynamic commercial opportunities. Bangladesh faces persistent gaps in healthcare infrastructure and quality and access to care. Urban centers such as Dhaka and Chattogram host leading private hospitals and diagnostic chains, while rural areas often lack access to basic services. The government operates a three-tiered system of community clinics, district hospitals, and tertiary facilities, but capacity is insufficient relative to population size. Because the private sector delivers 70-80 percent of care, there has been rapid growth in diagnostic centers, private hospitals, and telemedicine platforms. This growth creates openings for U.S. firms in medical devices, digital health solutions, and high-end pharmaceuticals.
Medical Devices
According to the Bangladesh Investment Development Authority (BIDA), the medical device sector is projected to nearly double from $442 million in 2020 to $820 million by 2025, driven by an aging population, a rising prevalence of non-communicable diseases, and an expanding network of healthcare facilities. The Bangladesh healthcare market is cost-sensitive and highly competitive, with Chinese and Indian suppliers dominating. However, rising incomes, an expanding middle class, and increasing demand for specialized care offer opportunities for U.S. firms because of their quality, innovation, and training support. Bangladesh offers opportunities for U.S. exporters of high-end medical equipment, surgical instruments, diagnostic equipment, and services.
Pharmaceuticals
Bangladesh is the only LDC that meets nearly 98 percent of its domestic demand for pharmaceutical products, with a market size of approximately $6 billion. Over 200 pharmaceutical companies are active in Bangladesh; the top ten producers make up approximately two-thirds of the market. Bangladesh exports about $200 million in pharmaceutical products to approximately 150 countries. The Government of Bangladesh encourages foreign companies to partner with local companies in producing drugs and high-tech and specialized products.
Regulatory and Policy Environment
Healthcare is a priority in the government’s development plans, which call for universal health coverage and greater investment in non-communicable disease prevention. Yet public spending remains low compared to regional peers. Donor-funded programs from the World Health Organization, Global Fund, U.S. Center for Disease Control and Prevention, Asian Development Bank, World Bank, United Nations International Children’s Emergency Fund, United Nations Development Programme, International Federation of Red Cross and Red Crescent, European Union, GAVI, Swedish International Development Cooperation Agency, and United Nations Office for Project Services continue to play a critical role in infectious disease management and health system strengthening.
The Ministry of Health and Family Welfare (MOHFW) is responsible for formulating national-level policy, planning, and decision-making concerning healthcare and education, which are translated into action by various implementing authorities and healthcare delivery systems across the country, from the national to the community level. The Ministry and its relevant regulatory bodies also have indirect control over the healthcare system of the non-governmental organizations and the private sector. Most high-quality medical institutions are in Dhaka, which acts as the hub for disseminating medical services across the country. The private health sector plays a substantial and complex role in supporting Bangladesh’s healthcare system, filling critical gaps in service delivery and accounting for approximately 64 percent ($1.49 billion) of the country’s total health expenditure. Currently, the private sector operates about 6,000 clinics and hospitals and 12,000 diagnostic centers.
Bangladesh’s Directorate General of Health Services (DGHS) serves as the primary implementation arm of the MOHFW, responsible for implementing health programs, managing health services, and executing national health policies to advance universal health coverage. Key roles include health management, policy implementation, technical assistance to the ministry, and coordinating various health-related activities across the nation to ensure effective healthcare delivery.
The Directorate General of Drug Administration (DGDA) oversees drug approvals, imports, and quality standards. However, the DGDA is under-resourced, leading to delays in product registration and approvals. Most medical devices require registration with DGDA, customs procedures can be lengthy, and a lack of harmonization with international standards can create compliance challenges for U.S. exporters. Moreover, tariffs can be high on certain equipment.
Healthcare investors in Bangladesh must submit a project proposal to the BIDA for review before receiving approval. Once registered with BIDA, companies investing in hospitals and medical education must obtain a license from the DGHS. Pharmaceutical and medical device companies in turn must go through DGDA for licensing. However, companies seeking these licenses will be reviewed by MOHFW (or health‑related arms, including DGHS or DGDA) for eligibility, suitability, compliance with health policy, safety, etc., before licensing. For medical device registration with the DGDA, the timeline for approval is often cited as 4‑6 months for new registrations.
Opportunities
- Generic Pharmaceuticals: The backbone of Bangladesh’s pharma sector; opportunities for quality control systems and manufacturing technology.
- Specialized and High-End Drugs: Growing demand for biologics, cancer therapies, cardiovascular drugs, and rare-disease treatments.
- Vaccines and Biotech: Expanding interest in biotech research and development and vaccine production partnerships, with opportunities for joint ventures.
- Medical Devices and Diagnostics: Increasing demand for imaging equipment, diagnostic kits, surgical instruments, surgical implants and prosthetics, and laboratory systems.
- Digital Health and Telemedicine: Accelerated adoption since COVID-19, with room for U.S. companies offering cloud-based health IT, AI-enabled diagnostics, and telehealth platforms.
- Hospital Infrastructure and Training: Demand for modern operating theaters, intensive care units, and skills development programs for healthcare professionals.
- Others: Dietary supplements; pharmacovigilance; cosmetics; veterinary and human vaccines; disease modifying drugs; hormonal therapies; health insurances; home care solutions for geriatric/palliative care.